Immunoglobulin kappa chain as an immunologic biomarker of prognosis and chemotherapy response in solid tumors

OncoImmunology

Volumn 1, Issue 7, 2012, Pages 1156-1158

  Schmidt, Marcus ^a   Micke, Patrick ^b   Gehrmann, Mathias ^c   Hengstler, Jan G ^d  

^a UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

^b UPPSALA UNIVERSITY   (Sweden)

^c BAYER AG   (Germany)

^d LEIBNIZ RESEARCH CENTRE FOR WORKING ENVIRONMENT AND HUMAN FACTORS   (Germany)

Author keywords

Breast cancer prognosis; Colon cancer; Humoral immune system; Immunoglobulin kappa C; Lung cancer; Prediction of chemotherapy response; Prognosis

Indexed keywords

ANTHRACYCLINE DERIVATIVE; BIOLOGICAL MARKER; CETUXIMAB; IMMUNOGLOBULIN KAPPA CHAIN; RITUXIMAB; TRASTUZUMAB;

ADJUVANT CHEMOTHERAPY; ARTICLE; B LYMPHOCYTE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; COLORECTAL CARCINOMA; GENE EXPRESSION; HUMAN; IMMUNE SYSTEM; LUNG NON SMALL CELL CANCER; PRIORITY JOURNAL; SOLID TUMOR; TREATMENT OUTCOME; TREATMENT RESPONSE;

EID: 84886944497     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.4161/onci.21653     Document Type: Article

References (25)

1. Schmidt M, Victor A, Bratzel D, Boehm D, Cotarelo C, Lebrecht A, et al. Long-term outcome prediction by clinicopathological risk classification algorithms in node-negative breast cancer--comparison between Adjuvant! St Gallen, and a novel risk algorithm used in the prospective randomized Node-Negative-Breast Cancer-3 (NNBC-3) trial. Ann Oncol 2009; 20:258-64; PMID:18824499; http://dx.doi.org/10.1093/annonc/mdn590.
2. van't Veer LJ, Dai H, van de Vijver MJ, He YD, Hart AA, Mao M, et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002; 415:530-6; PMID:11823860; http://dx.doi.org/10.1038/415530a.
3. Wang Y, Klijn JG, Zhang Y, Sieuwerts AM, Look MP, Yang F, et al. Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. Lancet 2005; 365:671-9; PMID:15721472.
4. Kammers K, Lang M, Hengstler JG, Schmidt M, Rahnenführer J. Survival models with preclustered gene groups as covariates. BMC Bioinformatics 2011; 12:478; PMID:22177110; http://dx.doi.org/10.1186/1471-2105-12-478.
5. Hellwig B, Hengstler JG, Schmidt M, Gehrmann MC, Schormann W, Rahnenführer J. Comparison of scores for bimodality of gene expression distributions and genome-wide evaluation of the prognostic relevance of high-scoring genes. BMC Bioinformatics 2010; 11:276; PMID:20500820; http://dx.doi.org/10.1186/1471-2105-11-276.
6. Paik S, Shak S, Tang G, Kim C, Baker J, Cronin M, et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 2004; 351:2817-26; PMID:15591335; http://dx.doi.org/10.1056/NEJMoa041588.
7. Sotiriou C, Wirapati P, Loi S, Harris A, Fox S, Smeds J, et al. Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis. J Natl Cancer Inst 2006; 98:262-72; PMID:16478745; http://dx.doi.org/10.1093/jnci/djj052.
8. Fan C, Oh DS, Wessels L, Weigelt B, Nuyten DS, Nobel AB, et al. Concordance among gene-expression- based predictors for breast cancer. N Engl J Med 2006; 355:560-9; PMID:16899776; http://dx.doi.org/10.1056/NEJMoa052933.
9. Petry IB, Fieber E, Schmidt M, Gehrmann M, Gebhard S, Hermes M, et al. ERBB2 induces an antiapoptotic expression pattern of Bcl-2 family members in node-negative breast cancer. Clin Cancer Res 2010; 16:451-60; PMID:20068093; http://dx.doi.org/10.1158/1078-0432.CCR-09-1617.
10. Schmidt M, Hengstler JG, von Törne C, Koelbl H, Gehrmann MC. Coordinates in the universe of node-negative breast cancer revisited. Cancer Res 2009; 69:2695-8; PMID:19318558; http://dx.doi.org/10.1158/0008-5472.CAN-08-4013.
11. Schmidt M, Petry IB, Böhm D, Lebrecht A, von Törne C, Gebhard S, et al. Ep-CAM RNA expression predicts metastasis-free survival in three cohorts of untreated node-negative breast cancer. Breast Cancer Res Treat 2011; 125:637-46; PMID:20352488; http://dx.doi.org/10.1007/s10549-010-0856-5.
12. Perou CM, Sørlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, et al. Molecular portraits of human breast tumours. Nature 2000; 406:747-52; PMID:10963602; http://dx.doi.org/10.1038/35021093.
13. Sørlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 2001; 98:10869-74; PMID:11553815; http://dx.doi.org/10.1073/pnas.191367098.
14. Rouzier R, Perou CM, Symmans WF, Ibrahim N, Cristofanilli M, Anderson K, et al. Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin Cancer Res 2005; 11:5678-85; PMID:16115903; http://dx.doi.org/10.1158/1078-0432.CCR-04-2421.
15. Cadenas C. Prognostic signatures of breast cancer: Perou's molecular subtypes and Schmidt's metagenes. EXCLI J 2012; 11:204-7.
16. Schmidt M, Böhm D, von Törne C, Steiner E, Puhl A, Pilch H, et al. The humoral immune system has a key prognostic impact in node-negative breast cancer. Cancer Res 2008; 68:5405-13; PMID:18593943; http://dx.doi.org/10.1158/0008-5472.CAN-07-5206.
17. Marchan R, Stewart JD, Lesjak M. EDI3, a key enzyme of choline metabolism controls tumour cell migration. EXCLI J 2012; 11:260-2.
18. Schmidt M, Hellwig B, Hammad S, Othman A, Lohr M, Chen Z, et al. A comprehensive analysis of human gene expression profiles identifies stromal immunoglobulin κ C as a compatible prognostic marker in human solid tumors. Clin Cancer Res 2012; 18:2695-703; PMID:22351685; http://dx.doi.org/10.1158/1078-0432.CCR-11-2210.
19. Whiteside TL, Ferrone S. For breast cancer prognosis, immunoglobulin kappa chain surfaces to the top. Clin Cancer Res 2012; 18:2417-9; PMID:22442060; http://dx.doi.org/10.1158/1078-0432.CCR-12-0566.
20. Cadenas C, Franckenstein D, Schmidt M, Gehrmann M, Hermes M, Geppert B, et al. Role of thioredoxin reductase 1 and thioredoxin interacting protein in prognosis of breast cancer. Breast Cancer Res 2010; 12:R44; PMID:20584310; http://dx.doi.org/10.1186/bcr2599.
21. Martin M, Müller K, Cadenas C, Hermes M, Zink M, Hengstler JG, et al. ERBB2 overexpression triggers transient high mechanoactivity of breast tumor cells. Cytoskeleton (Hoboken) 2012; 69:267-77; PMID:22407943; http://dx.doi.org/10.1002/cm.21023.
22. Stewart JD, Marchan R, Lesjak MS, Lambert J, Hergenroeder R, Ellis JK, et al. Choline-releasing glycerophosphodiesterase EDI3 drives tumor cell migration and metastasis. Proc Natl Acad Sci USA 2012; 109:8155-60; PMID:22570503; http://dx.doi.org/10.1073/pnas.1117654109.
23. Cadenas C, Vosbeck S, Hein EM, Hellwig B, Langer A, Hayen H, et al. Glycerophospholipid profile in oncogene-induced senescence. Biochim Biophys Acta 2012; 1821:1256-68; PMID:22178194; http://dx.doi.org/10.1016/j.bbalip.2011.11.008.
24. Tan TT, Coussens LM. Humoral immunity, inf lammation and cancer. Curr Opin Immunol 2007; 19:209-16; PMID:17276050; http://dx.doi.org/10.1016/j.coi.2007.01.001.
25. Inoue S, Leitner WW, Golding B, Scott D. Inhibitory effects of B cells on antitumor immunity. Cancer Res 2006; 66:7741-7; PMID:16885377; http://dx.doi.org/10.1158/0008-5472.CAN-05-3766.